clinical trial · NCT03610789
A Multicenter, Post-Market Clinical Follow-up Study of Subjects With the REDAPT™ System Monolithic Sleeveless/Sleeved Stem and/or Fully Porous Acetabular Shell With XLPE Liner and/or Modular Shell Components Previously Implanted
Smith & Nephew, Inc.·—·enrolling by invitation·n = 220
Hip ReplacementREDAPT
brief summary
The primary purpose of this study is to demonstrate cumulative revision rate of the REDAPT System Monolithic Sleeveless/Sleeved Stem, Fully Porous Acetabular Shell with XLPE liner, and Modular Shell Components (with or without Staple, Slice and Blade Augments) at 10 years.
started
May 7, 2018
primary completion
Jul 1, 2034
completion
Jul 1, 2034
last updated
Jan 6, 2025
detailed description
Retrospective-prospective, single arm, multicenter study of subjects previously implanted with the REDAPT System Monolithic Sleeveless/Sleeved Stem and/or Fully Porous Acetabular Shell with XLPE liner and/or Modular Shell Components (with or without Staple, Slice and Blade Augments).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol